Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

Egyptian Liver Journal

Table 6 Comparison between fibroscan results in the studied patients

		At the start of treatment		1 month of treatment		At the end of treatment		P-value
Fibroscan	F0–F1	113	56.5%	113	56.5%	111	55.5%	P1 = 1.0 NS P2 = 0.973 NS P3 = 0.973 NS
	F1–F2	55	27.5%	55	27.5%	57	28.5%
	F3–F4	32	16.5%	32	16.5%	32	16.5%

X²: chi-square test
S: p-value < 0.05 is considered significant
HS: p-value < 0.001 is considered highly significant
P1: refers to the statistical difference between the start of DAA and 1 month after DAA
P2: refers to the statistical difference between the start of DAA and the end of DAA
P3: refers to the statistical difference between 1 month after DAA and the end of DAA